
Pregnancy outcomes following exposure to abatacept during pregnancy
Keywords: Pregnancy; Abatacept; Exposure; Congenital anomalies; Biological disease-modifying antirheumatic drugs; DMARD; disease-modifying antirheumatic drug; FDA; Food and Drug Administration; MADCF; Metropolitan Atlanta Congenital Defects Program; MMF; mycophenol